Silence Therapeutics PLC Appoints David Horn Solomon as CEO (8998U)
July 17 2018 - 8:00AM
UK Regulatory
TIDMSLN
RNS Number : 8998U
Silence Therapeutics PLC
17 July 2018
Silence Therapeutics Appoints David Horn Solomon as Chief
Executive Officer
17 July 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery and development of novel RNA therapeutics
announces today the appointment of Dr David Horn Solomon as its new
Chief Executive Officer (CEO) effective immediately. David will
head the Leadership Team and joins the Board of Directors.
David is an experienced public company biotech CEO, board member
and biotech investor. He was the CEO of Zealand Pharma A/S
(NASDAQ:ZEAL) from 2008 to 2015. Under David's leadership the
company went public on NASDAQ OMX and its lead product, Adlixin(R),
a GLP-1 receptor agonist for the treatment of type II diabetes, was
approved in the US and globally and is now marketed by Sanofi as a
monotherapy and in combination with Lantus as Soliqua(R). David was
also the CEO of Bionor Pharma ASA (OSL:BIONOR) and Akari
Therapeutics, Plc (NASDAQ:AKTX), and was the Managing Partner of
Sund Capital, ApS, a Nordic healthcare investment fund.
He has earlier served as a faculty member at Columbia
University's College of Physicians and Surgeons in New York City.
From 2003 to 2006, David headed healthcare investment at Carrot
Capital Healthcare Ventures in New York. David is currently a
member of the Board of Directors of TxCell SA (NYSE EURONEXT:TXCL),
and was earlier a member of the Boards at Onxeo SA (NYSE
EURONEXT:ONXEO) and Promosome, LLC. Dr Solomon studied at Weil
Cornell Medicine of Cornell University and its Graduate School of
Medical Science where he received his Ph.D. David expects to
receive full authorisation to work in the UK shortly.
Commenting on the appointment, Annalisa Jenkins, Executive Chair
of Silence Therapeutics, said:
"I am thrilled to be welcoming David to lead the Company through
its next phase of growth. Having held senior management roles in
both the US and Europe, David brings extensive international
leadership experience in the biotech industry with a track record
of successful pipeline delivery, financing and deal making. Silence
is now a leading RNAi company building the next generation of
programmes based upon our proprietary technology platform in
GalNAc-conjugated siRNA. With David at the helm as CEO, supported
by a very experienced team and Board, Silence is in a strong
position to maximise the potential of our IP and technology through
strong collaborations and the advancement of our internal
programmes toward the clinic, with our lead candidate SLN124
becoming a clinical stage asset in the coming year."
David Horn Solomon, newly appointed Chief Executive Officer of
Silence Therapeutics, added:
"In this age of RNAi, Silence's world class RNAi platform offers
an exciting opportunity to build a competitive drug development
company with global relevance. I am particularly impressed with the
near-term opportunities including the lead programme in iron
overload disorders which is progressing toward clinical trials. I
am very pleased to join Silence at this critical juncture for both
the sector and patients. I look forward to working with the highly
accomplished Leadership Team and Board of Directors as we translate
the excellent science into meaningful value for both patients and
investors."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Full name and age: David Horn Solomon, aged 57. He holds no
ordinary shares in the Company.
Current Directorships or Partnerships:
TxCell SA
Tyler Hill Holdings ApS
Solomon-Solvberg Sons and Daughters
Previous Directorships or Partnerships:
(1)Akari Therapeutics, Plc
Onxeo SA
Promosome, LLC
Sund Capital, ApS
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
Aim Rules for Companies.
Enquiries:
Silence Therapeutics plc Tel: +44 (0) 20 3457
Annalisa Jenkins, Executive Chair 6900
David Solomon, Chief Executive Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0) 20 7418
James Steel/ Oliver Jackson 8900
Media & IR Enquiries Tel: +44 (0) 20 3714
Optimum Strategic Communications 1788
Mary Clark/ Eva Haas/ Hollie Vile
silence@optimumcomms.com
IR Enquiries - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
Silence.Therapeutics@burnsmc.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new modality of genetic
medicines by harnessing the body's natural mechanism of RNA
interference, or RNAi, within its cells. Its proprietary technology
can selectively inhibit any gene in the genome and be engineered to
specifically silence the production of disease-associated proteins.
Using enabling delivery systems, Silence has achieved an additional
level of specificity by delivering therapeutic RNA molecules
exclusively to target cells. Silence's proprietary technology
platform provides an effective, safe and highly potent modular
approach well suited to tackling life-threatening diseases. Silence
aims on being a clinical stage company in 2019, while progressing a
pipeline of earlier stage candidates against important gene targets
directed at areas of high unmet medical need. In parallel, Silence
continues to evolve its patent portfolio as new discoveries emerge
from its innovative efforts to develop the next generation of RNAi
medicines.
Silence has out-licensed technology to Quark Pharmaceuticals for
use in Delayed Graft Function and Acute Kidney Injury. Both
programmes are now in phase III. For more information, please
visit: http://www.silence-therapeutics.com/
(1)On 8 May 2018 Dr. David Solomon resigned as Chief Executive
Officer and as a member of the Board of Akari Therapeutics, Plc
("Akari"). Akari, a NASDAQ quoted company, issued a Form 6-K on 11
May 2018 related to his resignation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALLFFIDTIDLIT
(END) Dow Jones Newswires
July 17, 2018 08:00 ET (12:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024